Skip to main content

Table 2 Adverse events reported and recorded during the in-hospital period

From: The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the Prostaglandin E2 human model of headache

 

Placebo plus PGE2

BGC20-1531 200 mg plus PGE2

BGC20-1531 400 mg plus PGE2

Headache

6

6

7

Nausea

2

0

2

Photophobia

1

2

3

Phonophobia

0

0

0

Flushing

8

8

7

Heat sensation

6

5

5

Palpitation

4

7

4

Low back pain

1

0

1

Tightness in chest

4

3

2

Stiff muscles

2

1

2

Chills

1

1

0

Increased mucus production in throat

3

2

2

Parasthesia lips/fingers/arm

1

1

2

Local irritation around injection place

1

3

1

Low abdominal pain which mimics menstruation

1

1

1

Urge to void

3

1

2

Thirst

3

2

2

Face heat sensation

0

0

1

  1. There was no difference between occurrence of AEs on placebo and BGC20-1531 200 mg pretreatment and BGC20-1531 400 mg pretreatment (P > 0.05, McNemar test)